Catabasis Pharmaceuticals Announces Closing of $11.5 Million Offering of Common Stock, Including Full
Exercise of Underwriter’s Option to Purchase Additional Shares
Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage pharmaceutical company, today announced the
closing of an underwritten offering of 2,875,000 shares of its common stock, including 375,000 shares purchased by the underwriter
pursuant to the exercise in full of its option to purchase additional shares, at a price of $4.00 per share. Catabasis received
gross proceeds of $11.5 million, before deducting underwriting discounts and commissions and other offering expenses. Catabasis
intends to use the net proceeds from the sale of the offered securities to fund its ongoing and planned clinical trials of
edasalonexent (CAT-1004), to fund market development activities for edasalonexent, to fund research and development to advance its
pipeline of preclinical product candidates and expand its product platform, and for working capital and general corporate
purposes.
Cowen and Company, LLC acted as sole book-running manager for the offering.
The securities described above were offered pursuant to a shelf registration statement (File No. 333-212382), which was declared
effective by the Securities and Exchange Commission on July 19, 2016. This offering was made only by means of a prospectus
supplement and the accompanying prospectus. A final prospectus supplement relating to the offering has been filed with the
Securities and Exchange Commission and is available at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus may be obtained by
contacting Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue,
Edgewood, NY 11717, by telephone at (631) 274-2806, or by fax at (631) 254-7140.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall
there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such jurisdiction.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART
(Safely Metabolized And Rationally Targeted) linker drug discovery platform enables us to engineer molecules that simultaneously
modulate multiple targets in a disease. We are applying our SMART linker platform to build an internal pipeline of product
candidates for rare diseases and plan to pursue partnerships to develop additional product candidates.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about
future clinical trial plans and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “may” and
similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important
factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical
development of the Company’s product candidates; availability and timing of results from preclinical studies and clinical trials;
whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials;
expectations for regulatory approvals to conduct trials or to market products; availability of funding sufficient for the Company’s
foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the
availability or commercial potential of the Company’s product candidates; and general economic and market conditions and other
factors discussed in the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2016,
which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities
and Exchange Commission in the future. In addition, the forward-looking statements included in this press release represent the
Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause
the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the date of this release.
Corporate and Media Contact
Catabasis Pharmaceuticals, Inc.
Andrea Matthews, 617-349-1971
amatthews@catabasis.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160928006287/en/